lunedì, 20 marzo 2023

Notizie AIOM – anno XVI n. 693

Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism

Understanding sex differences in colon cancer is essential to advance disease prevention, diagnosis, and treatment. Males have a higher risk of developing colon cancer and a lower survival rate than women. However, the molecular features that drive these sex differences ...
Leggi tutto

Dal Soroptimist International Club Genova a favore delle ragazze STEM

Il Premio, del valore di 2.000 Euro, sarà attribuito ad una Tesi di Laurea Magistrale in campo Emato-Oncologico, discussa da una studentessa dell’Università degli Studi di Genova negli anni accademici 2016-17 o 2017-18, in una delle seguenti discipline: ...
Leggi tutto

Sex Differences in Cancer Driver Genes and Biomarkers

Cancer differs significantly between men and women; even after adjusting for known epidemiologic risk factors, the sexes differ in incidence, outcome, and response to therapy. These differences occur in many but not all tumor types, and their origins remain largely unknown. ...
Leggi tutto

ASCP, CAP, and ASH Invite Public Comment on Lymphoma Guideline

October 5, 2018 - With a focus on the pathology aspects of diagnosing lymphoma, the American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), and the American Society of Hematology (ASH) are collaborating to develop an evidence-based clinical ...
Leggi tutto

ASCO Statement on JAMA Study on Cancer Disparities in the U.S.

October 5, 2018 - "This study reinforces the unfortunate reality that too many Americans can't access quality cancer care despite the progress we have made in understanding and treating the disease. All patients deserve access to high quality care, but where they live often ...
Leggi tutto

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

October 1, 2018 - The FDA has approved a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma, according to Amgen, the manufacturer of the proteasome inhibitor. The approval is based on results ...
Leggi tutto

NGS Assay for MRD Detection Gains FDA Approval for 2 Blood Cancers

October 2, 2018 - The FDA has approved the next-generation sequencing (NGS) assay clonoSEQ as a test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma. The vitro diagnostic, which is manufactured by Adaptive Biotechnologies, ...
Leggi tutto

FDA approves expanded use of Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant to include individuals 27 through 45 years old

October 5, 2018 - The U.S. Food and Drug Administration today approved a supplemental application for Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant, expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Human Papillomavirus ...
Leggi tutto

FDA Grants Selinexor Priority Review for Multiple Myeloma

October 6, 2018 - The FDA has granted a priority review to a new drug application (NDA) for selinexor for the treatment of patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics, the manufacturer of the XPO1 inhibitor. The NDA is based on results ...
Leggi tutto

EMA Management Board: highlights of October 2018 meeting

October 5, 2018 - At its 4 October 2018 meeting in London, the Management Board of the European Medicines Agency (EMA) heard an update on the Agency’s activities in the first half of 2018. In human medicine, EMA recommended the first two CAR-T cell medicines for approval ...
Leggi tutto